REPL
Replimune Group, Inc. Health Care Biological Products, (No Diagnostic Substances) Russell 3000
$17.61Close
$1.5BMarket cap
$1.70 – $17.6152-week range
Late-januaryNext report · estimated
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
- Leading the market RS 99 · stronger than 99% of stocks over 12 months
- RS line at a 1-year high outperforming the S&P 500 more than at any point this year
- Near its high at its 52-week high
Cautions
- Extended 4.6 ATR above its 50-day average
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
0%
1wk
up 53.7%
price change
1mo
up 33.0%
price change
12-month return
up 72%
market up 11% ·
its own up 62%
F-score
—
— Not assessed
Altman Z
—
Unknown
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
8.8×
price / book
Earnings yield
down 24.0%
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
—
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
down 108%
return on equity
Free cash margin
—
-$284.6M FCF
D/E
0.50
long-term debt / equity
Net debt / EBITDA
—
Interest cover
Lossoperating loss
Trade setup
ATR%
6.4%
$1.12 a day · 2×ATR $15.36
RS
99 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
1.7×
vs 50-day average
Up/down volume
1.48
50 sessions
Implied move
—
no scheduled report
Trend template · 8 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Losing money before interest is even paid The company made an operating loss, so interest is not covered at all - the debt is being serviced from cash reserves, asset sales or new borrowing rather than from the business.
- Shareholders diluted The share count rose 7.3% over the year, from 77m to 83m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Oct 28, 2026
Last shock
Jul 28, 2026-38% in one session6.1× volumeon an SEC filing+229% since
Financials
- Cash
- Long-term debt
| FY2021Mar 31, 2021 | FY2022Mar 31, 2022 | FY2023Mar 31, 2023 | FY2024Mar 31, 2024 | FY2025Mar 31, 2025 | FY2026Mar 31, 2026 | |
|---|---|---|---|---|---|---|
| Operating income | -$80.0M | -$118.3M | -$177.1M | -$234.8M | -$261.6M | -$319.9M |
| Net income | -$80.9M | -$118.0M | -$174.3M | -$215.8M | -$247.3M | -$313.9M |
| Earnings per share | -$1.75 | -$2.26 | -$2.99 | -$3.24 | -$3.07 | -$3.38 |
| Free cash flow | -$63.8M | -$84.5M | -$130.3M | -$191.1M | -$198.9M | -$284.6M |
| Cash | $182.5M | $105.9M | $146.6M | $74.5M | $111.1M | $209.0M |
| Long-term debt | — | $0 | $28.6M | $44.8M | $46.4M | $83.3M |
| Shareholders' equity | $498.7M | $411.2M | $555.3M | $374.5M | $415.8M | $166.2M |
| Shares outstanding | 46.57m | 47.34m | 56.68m | 61.42m | 77.09m | 82.72m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Oct 28, 2026 | Quarterly ↗ | Sep 30, 2026 | 28d |
| Aug 14, 2026 | Quarterly ↗ | Jun 30, 2026 | 45d |
| Jun 29, 2026 | Annual ↗ | Mar 31, 2026 | 90d |
| Feb 3, 2026 | Quarterly ↗ | Dec 31, 2025 | 34d |
| Nov 6, 2025 | Quarterly ↗ | Sep 30, 2025 | 37d |
| Aug 7, 2025 | Quarterly ↗ | Jun 30, 2025 | 38d |
| May 22, 2025 | Annual ↗ | Mar 31, 2025 | 52d |
| Feb 12, 2025 | Quarterly ↗ | Dec 31, 2024 | 43d |
| Nov 12, 2024 | Quarterly ↗ | Sep 30, 2024 | 43d |
| Aug 8, 2024 | Quarterly ↗ | Jun 30, 2024 | 39d |
| May 16, 2024 | Annual ↗ | Mar 31, 2024 | 46d |
| Feb 8, 2024 | Quarterly ↗ | Dec 31, 2023 | 39d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 28, 2026 | Results ↗ |
| Sep 16, 2026 | Charter or bylaws · Shareholder vote ↗ |
| Aug 14, 2026 | Results ↗ |
| Aug 10, 2026 | Other events ↗ |
| Aug 7, 2026 | Other events ↗ |
| Jul 31, 2026 | Other events ↗ |
| Jul 30, 2026 | Regulation FD ↗ |
| Jun 29, 2026 | Results ↗ |
| Jun 26, 2026 | Regulation FD ↗ |
| May 29, 2026 | Regulation FD ↗ |
| Apr 13, 2026 | Regulation FD · Other events ↗ |
| Feb 3, 2026 | Material agreement · Results · New obligation ↗ |